News Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Real-time Estimate Cboe Europe Other stock markets 03:46:11 2024-04-16 am EDT			5-day change	1st Jan Change
8.99 ^CHF	-1.21%		-6.73%	-6.83%

Mar. 27	Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	MT
Mar. 27	Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	Mar. 27	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	Mar. 14	AQ
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14	MT
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	Feb. 14	AQ
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	AQ
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	Jan. 12	MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	Jan. 12	MT
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom	Jan. 12	AQ
Swiss Equities Edge Down After Central Banks Buzz	Dec. 18	MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug	Dec. 18	MT
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	Dec. 18	AQ
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers	Dec. 07	MT
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage	Dec. 07	AQ
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer	Dec. 07	CI
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals	23-10-27	AQ
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Summary

Filters